Y. Shi

Assessment of an Anti-Alpha-Toxin Monoclonal Antibody for Prevention and Treatment of Staphylococcus aureus-Induced Pneumonia

J. Suzich, B. Sellman, G. Robbie, 2013, Antimicrobial Agents and Chemotherapy.

MEDI4893* Promotes Survival and Extends the Antibiotic Treatment Window in a Staphylococcus aureus Immunocompromised Pneumonia Model

J. Suzich, B. Sellman, V. Datta, 2015, Antimicrobial Agents and Chemotherapy.

Identification of Anti-Alpha Toxin Monoclonal Antibodies That Reduce the Severity of Staphylococcus aureus Dermonecrosis and Exhibit a Correlation between Affinity and Potency

R. Woods, Susan D. Wilson, R. S. MacGill, 2012, Clinical and Vaccine Immunology.

Targeting Alpha Toxin and ClfA with a Multimechanistic Monoclonal-Antibody-Based Approach for Prophylaxis of Serious Staphylococcus aureus Disease

J. Suzich, B. Sellman, B. Kreiswirth, 2016, mBio.

Multimechanistic Monoclonal Antibodies (MAbs) Targeting Staphylococcus aureus Alpha-Toxin and Clumping Factor A: Activity and Efficacy Comparisons of a MAb Combination and an Engineered Bispecific Antibody Approach

D. Corti, A. Minola, B. Sellman, 2017, Antimicrobial Agents and Chemotherapy.

MEDI4893* Promotes Survival and Extends the Antibiotic Treatment Window in a Staphylococcus aureus Immunocompromised Pneumonia Model

J. Suzich, B. Sellman, C. Tkaczyk, 2015, Antimicrobial Agents and Chemotherapy.

Alanine Scanning Mutagenesis of the MEDI4893 (Suvratoxumab) Epitope Reduces Alpha Toxin Lytic Activity In Vitro and Staphylococcus aureus Fitness in Infection Models

B. Sellman, P. Warrener, V. Oganesyan, 2018, Antimicrobial Agents and Chemotherapy.